1-苯基-1,3,8-三氮杂螺[4.5]癸-2-烯-4-酮 | 265107-18-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氮杂螺癸烷衍生物
• 中文名称: 1-苯基-1,3,8-三氮杂螺[4.5]癸-2-烯-4-酮
• 英文名称: 1-Phenyl-1,3,8-triazaspiro[4.5]dec-2-en-4-one
• CAS: 265107-18-4
• 化学式: C₁₃H₁₅N₃O
• 分子量: 229.282
• InChiKey: BLWGUFZKABRLPD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  44.7
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-苯基-1,3,8-三氮杂螺[4.5]癸-2-烯-4-酮 在 sodium hydride 、 sodium carbonate 作用下， 以 1,4-二氧六环 、 甲醇 、 水 为溶剂， 反应 26.5h， 生成 (8-{[(2-甲基-2-丙基)氧基]羰基}-4-氧代-1-苯基-1,3,8-三氮杂螺[4.5]癸-3-基)乙酸
  参考文献：
  名称：

  Synthesis and Characterization of Pseudopeptide Bradykinin B2 Receptor Antagonists Containing the 1,3,8-Triazaspiro[4.5]decan-4-one Ring System

  摘要：

  A series of pseudopeptides containing alkyl-, cycloalkyl-, aryl-, and aralkyl-substituted 1,3,8-triazaspiro[4.5]decan-4-one-3-acetic acids as amino acid surrogates to replace the Pro(2)-Pro(3)-Gly(4)-Phe(5) section of the peptide bradykinin B2 receptor antagonist [Pro(3), Phe(5)]HOE 140 (D-Arg(0)-Arg(1)-Pro(2)-Pro(3)-Gly(4)-Phe(5)-Ser(6)-D-Tic(7)-Oic(8)-Arg(9)) were prepared. These psuedopeptides were examined in vitro for their B2 receptor affinities as well as for their ability to block bradykinin mediated actions in, vivo. Two compounds in particular, NPC 18521 (I) and NPC 18688 (V) were quite potent in these latter assays, indicating that a significant portion of this prototypical second generation decapeptide antagonist can be replaced with a more compact nonpeptide molecule.

  DOI：

  10.1021/jm950676i
• 作为产物：
  描述：

  4-苯胺基-1-苄基-4-氰基哌啶 在 palladium on activated charcoal 盐酸 、 硫酸 、 氢气 、 溶剂黄146 作用下， 以 甲醇 、 甲苯 为溶剂， 反应 136.0h， 生成 1-苯基-1,3,8-三氮杂螺[4.5]癸-2-烯-4-酮
  参考文献：
  名称：

  Synthesis and Characterization of Pseudopeptide Bradykinin B2 Receptor Antagonists Containing the 1,3,8-Triazaspiro[4.5]decan-4-one Ring System

  摘要：

  A series of pseudopeptides containing alkyl-, cycloalkyl-, aryl-, and aralkyl-substituted 1,3,8-triazaspiro[4.5]decan-4-one-3-acetic acids as amino acid surrogates to replace the Pro(2)-Pro(3)-Gly(4)-Phe(5) section of the peptide bradykinin B2 receptor antagonist [Pro(3), Phe(5)]HOE 140 (D-Arg(0)-Arg(1)-Pro(2)-Pro(3)-Gly(4)-Phe(5)-Ser(6)-D-Tic(7)-Oic(8)-Arg(9)) were prepared. These psuedopeptides were examined in vitro for their B2 receptor affinities as well as for their ability to block bradykinin mediated actions in, vivo. Two compounds in particular, NPC 18521 (I) and NPC 18688 (V) were quite potent in these latter assays, indicating that a significant portion of this prototypical second generation decapeptide antagonist can be replaced with a more compact nonpeptide molecule.

  DOI：

  10.1021/jm950676i

文献信息

• [EN] 5,7-DISUBSTITUTED-4-AMINOPYRIDO[2,3-D]PYRIMIDINE COMPOUNDS<br/>[FR] COMPOSES DE 4-AMINOPYRIDO[2,3-D]PYRIMIDINE A DISUBSTITUTION 5,7
  申请人：ABBOTT LAB

  公开号：WO2000023444A1

  公开（公告）日：2000-04-27

  A method of inhibiting adenosine kinase by administering one of more compounds of formula (I), wherein R?1, R2, R3 and R4¿ are defined, a pharmaceutical composition comprising a therapeutically effective amount of a compound thereof above in combination with a pharmaceutically acceptable carrier, and a method of treating cerebral ischemia, epilepsy, nociperception, inflammation and sepsis in a mammal in need of such treatment, comprising administering to the mammal a therapeutically effective amount of a compound thereof, a process for preparing said compounds, and compounds having the above formula wherein R?1, R2, R3 and R4¿ are separately defined.

  一种通过给予式(I)中的一个或多个化合物来抑制腺苷激酶的方法，其中R1、R2、R3和R4被定义，以及包含上述化合物的治疗有效量与药学可接受载体组合的制药组合物，以及一种治疗哺乳动物的脑缺血、癫痫、疼痛感知、炎症和败血症的方法，包括给予哺乳动物上述化合物的治疗有效量，制备上述化合物的方法以及具有上述式中R1、R2、R3和R4分别被定义的化合物。
• 1,3,8-Triuazaspiro(4,5)decanone compounds as ORL1-receptor agonists
  申请人：Pfizer Inc.

  公开号：US06465478B1

  公开（公告）日：2002-10-15

  A compound of formula: R1 and R2 are independently C1-C4 alkyl; or R1 and R2, taken together with the carbon atom to which they are attached, form a mono-, bi-, tri- or spiro-cyclic group having 3 to 13 carbon atoms, wherein the cyclic group is optionally substituted by one to five substituents; A is (C1-C3)alkyl, phenyl, benzyl or the like; R is hydrogen, (C1-C3)alkyl, amino-(C1-C6)alkyl, heterocyclic-(C1-C3)alkyl wherein the heterocyclic is optionally substituted by amino, ((C1-C4)alkyl)-Z—(C1-C6)alkyl wherein Z is OC(═O) or the like; and X is (C1-C3)alkyl, phenyl or the like. These compounds are useful as ORL1-receptor agonists, and useful as analgesics or the like in mammalian subjects.

  分子式为：R1和R2分别是C1-C4烷基；或者R1和R2与它们连接的碳原子共同形成具有3到13个碳原子的单环、双环、三环或螺环烷基，其中环烷基可选择性地被1到5个取代基取代；A是(C1-C3)烷基、苯基、苄基或类似物；R是氢、(C1-C3)烷基、氨基-(C1-C6)烷基、杂环-(C1-C3)烷基，其中杂环可选择性地被氨基、((C1-C4)烷基)-Z—(C1-C6)烷基取代，其中Z是OC(═O)或类似物；X是(C1-C3)烷基、苯基或类似物。这些化合物可用作ORL1受体激动剂，在哺乳动物主体中可用作镇痛剂或类似物。
• 1,3,8-Triazaspiro[4,5] decanone compounds as orl1-receptor agonists
  申请人：PFIZER INC.

  公开号：EP0997464A1

  公开（公告）日：2000-05-03

  A compound of the formula: R1 and R2 are independently C1-C4 alkyl; or R1 and R2, taken together with the carbon atom to which they are attached, form a mono-, bi-, tri- or spiro-cyclic group having 3 to 13 carbon atoms, wherein the cyclic group is optionally substituted by one to five substituents; A is (C1-C3)alkyl, phenyl, benzyl or the like; R is hydrogen, (C1-C3)alkyl, amino-(C1-C6)alkyl, heterocyclic-(C1-C3)alkyl wherein the heterocyclic is optionally substituted by amino, ((C1-C4)alkyl)-Z-(C1-C6)alkyl wherein Z is OC(=O) or the like; and X is (C1-C3)alkyl, phenyl or the like. These compounds are useful as ORL1-receptor agonists, and useful as analgesics or the like in mammalian subjects.

  式中的化合物： R1 和 R2 独立地为 C1-C4 烷基；或 R1 和 R2 与它们所连接的碳原子一起，形成具有 3 至 13 个碳原子的单环、双环、三环或螺环基团，其中环基团任选被 1 至 5 个取代基取代；A是(C1-C3)烷基、苯基、苄基或类似物；R是氢、(C1-C3)烷基、氨基-(C1-C6)烷基、杂环-(C1-C3)烷基（其中杂环任选被氨基取代）、((C1-C4)烷基)-Z-(C1-C6)烷基（其中 Z 是 OC(=O) 或类似物）；X是(C1-C3)烷基、苯基或类似物。这些化合物可用作 ORL1 受体激动剂，也可用作哺乳动物的镇痛剂或类似药物。
• SUBSTITUTED PYRROLIDIN-3-YL-ALKYL-PIPERIDINES USEFUL AS TACHYKININ ANTAGONISTS
  申请人：MERRELL PHARMACEUTICALS INC.

  公开号：EP0696280B1

  公开（公告）日：1997-09-24
• US5635510A
  申请人：——

  公开号：US5635510A

  公开（公告）日：1997-06-03